Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: A California Cancer Consortium trial

George Somlo, Ashkan Lashkari, William Bellamy, Todd M. Zimmerman, Joseph Tuscano, Margaret R. O'Donnell, Ann F. Mohrbacher, Stephen J. Forman, Paul Frankel, Helen X. Chen, James H. Doroshow, David R Gandara

Research output: Contribution to journalArticle

33 Scopus citations
Original languageEnglish (US)
Pages (from-to)533-535
Number of pages3
JournalBritish Journal of Haematology
Volume154
Issue number4
DOIs
StatePublished - Aug 2011

Keywords

  • Angiogenesis
  • Bevacizumab
  • Multiple myeloma
  • Thalidomide
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Hematology

Cite this

Somlo, G., Lashkari, A., Bellamy, W., Zimmerman, T. M., Tuscano, J., O'Donnell, M. R., Mohrbacher, A. F., Forman, S. J., Frankel, P., Chen, H. X., Doroshow, J. H., & Gandara, D. R. (2011). Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: A California Cancer Consortium trial. British Journal of Haematology, 154(4), 533-535. https://doi.org/10.1111/j.1365-2141.2011.08623.x